EXACT Sciences Corporation (NASDAQ:EXAS) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 10, 2016
Having a price of $19.83, EXACT Sciences Corporation (NASDAQ:EXAS) traded 2.85% higher on the day. With the last stock price up 56.34% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. EXAS has recorded a 50-day average of $19.36 and a two hundred day average of $12.68. Trade Volume was down over the average, with 1,218,176 shares of EXAS changing hands under the typical 3,895,360
Zacks Investment Research has downgraded EXACT Sciences Corporation (NASDAQ:EXAS) to Hold in a statement released on 10/10/2016.
On 10/04/2016, Jefferies & Co released a statement about EXACT Sciences Corporation (NASDAQ:EXAS) upped the target price from $20.00 to $23.00 that suggested an upside of 0.19%.
Recent Performance Chart
EXACT Sciences Corporation has with a one year low of $4.67 and a one year high of $22.80 and has a market capitalization of $0.
A total of 10 brokerages have released a report on EXACT Sciences Corporation. Five brokerages rating the company a strong buy, one brokerage rating the company a buy, seven brokerages rating the company a hold, zero brokerages rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $8.55.
General Company Details For EXACT Sciences Corporation (NASDAQ:EXAS)
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer. The Company's product pipeline includes Lung Cancer Nodules, Pancreatic Cancer Screening, Esophageal Cancer Screening, Lung Cancer Pipeline, Pancreatic Cancer Pipeline and Esophageal Cancer Pipeline. It has developed a non invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a non invasive stool based deoxyribonucleic acid (DNA) screening test designed to detect DNA markers. In addition to DNA markers, its test includes a protein marker to detect blood in the stool, utilizing an antibody based fecal immunochemical test. The United States Food and Drug Administration (FDA) approved Cologuard for use as sDNA non-invasive colorectal cancer screening test. Cologuard is available through healthcare providers. It also focused on developing its pipeline for future products and services.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.